Vall d'Hebron receives 2.6 million euros for research into advanced therapies

CERTERA's objective is to create a coordinated research and innovation structure to accelerate the preclinical and early stage clinical development of these types of therapies.

23/01/2024

The Vall d’Hebron University Hospital Accredited Health Institute (IIS-IR-HUVH) will receive 2.6 million euros over the next three years after being one of the centers selected by the Instituto de Salud Carlos III for the creation of the Spanish state consortium CERTERA in advanced therapies. The project, in which teams from Vall d'Hebron Research Institute (VHIR) and Vall d'Hebron Institute of Oncology (VHIO) collaborate, is the third that has received more funding in this call.

The objective of the State Network Consortium for the Development of Advanced Therapy Drugs (CERTERA) is to create a research and innovation structure that allows the coordination and amplification of the capacities and competences of the different entities that participate in order to provide pharmaceutical-quality development and production capacity for advanced therapy drugs in preclinical and early-stage clinical phases. It will also enable the establishment of strategic alliances with the industrial sector and facilitate the creation of an innovation ecosystem.

In this sense, Vall d'Hebron has two main structures designed for the development of advanced therapies: the Advanced Therapies Acceleration Unit of VHIO and the Vector Production Units, both viral and non-viral, of VHIR.

Regarding the VHIO's Advanced Therapies Acceleration Unit, it is mainly dedicated to the clinical development of cell therapies. The production of TIL cells, i.e. the patient's own lymphocytes, which are cultured and activated ex-vivo before being administered back to the patient with the aim of improving the response to the tumor, stand out. Also of interest are CAR-T cells, a treatment based on extracting cells from the immune system of patients, genetically modifying them and re-infusing them into the patient, stand out. In the case of tumors, this change allows the modified cells to attack the tumor cells.

Cell therapies require the use of vectors to introduce the modified genetic material into the cells. The Vector Production Unit is a technological platform of VHIR and the Autonomous University of Barcelona (UAB) that is responsible for the production, purification and characterization of viral vectors used for in vivo gene therapies led by public and private institutions at national and international level.

In addition, VHIR's Nanotechnology-Based Non-Viral Vector Production Unit is specialized in the use of nanoparticles for the creation of new vectors. These non-viral vectors, if used together with viral vectors, can help to improve CAR-T and TIL therapies.

This call, which has highlighted the capabilities and experience of Vall d'Hebron in the field of clinical trials and technology and knowledge transfer, will also help to advance all the research in advanced therapies that is developed in the Campus.

Share it:

Notícies relacionades

Related activities

Curs SedUCI 2024. Per una estratègia protectora. De la teoria a la pràctica

06/03/2024 - 08:30
Professionals involucrats en la cura del pacient crític i amb interès a oferir el millor maneig de la sedació, analgèsia i delirium.
More information

III Jornada Parkinson Vall d’Hebron '40 anys tractant i investigant la malaltia de Parkinson'

06/06/2024 - 15:30
More information

Escuela de Verano de genética asistencial. Aplicación práctica de la genética en contexto clínico

06/10/2024 - 16:00
More information

3er Curs Patologia Hipotàlem Hipofisiària

06/11/2024 - 08:15
Professionals sanitaris
More information

Subscribe to our newsletters and be a part of Campus Life

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.